Severity, criticality, and fatality of the SARS-CoV-2 Beta variant.
Abu-Raddad, Laith J;
Chemaitelly, Hiam;
Ayoub, Houssein H;
Yassine, Hadi M;
Benslimane, Fatiha M;
Al Khatib, Hebah A;
Tang, Patrick;
Hasan, Mohammad R;
Coyle, Peter;
AlMukdad, Sawsan;
+14 more...Al Kanaani, Zaina;
Al Kuwari, Einas;
Jeremijenko, Andrew;
Kaleeckal, Anvar Hassan;
Latif, Ali Nizar;
Shaik, Riyazuddin Mohammad;
Abdul Rahim, Hanan F;
Nasrallah, Gheyath K;
Al Kuwari, Mohamed Ghaith;
Butt, Adeel A;
Al Romaihi, Hamad Eid;
Al-Thani, Mohamed H;
Al Khal, Abdullatif;
Bertollini, Roberto;
(2021)
Severity, criticality, and fatality of the SARS-CoV-2 Beta variant.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
ciab909-.
ISSN 1058-4838
DOI: https://doi.org/10.1093/cid/ciab909
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Beta (B.1.351) variant COVID-19 disease was investigated in Qatar. Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta. Odds of progressing to critical disease were 1.49-fold (95% CI: 1.13-1.97) higher. Odds of COVID-19 death were 1.57-fold (95% CI: 1.03-2.43) higher.
